Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | BRAF | P15056 | 2/20 | 0.45 |
| ▸ | RAF1 | P04049 | 1/20 | 0.45 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | BRD2 | P25440 | 2/20 | 0.42 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.42 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4380603 | 0.92 | FGFR2 (0.50) | KDM4EFGFR2EGFRAURKAMEN1 | |
| SCHEMBL4380606 | 0.92 | FGFR2 (0.50) | KDM4EFGFR2EGFRAURKAMEN1 | |
| SCHEMBL7572002 | 0.91 | FGFR2 (0.51) | KDM4EFGFR2EGFRAURKAMEN1 | |
| SCHEMBL5217568 | 0.89 | EGFR (0.53) | ALDH1A1FGFR2EGFRMEN1KMT2A | |
| SCHEMBL5464557 | 0.86 | MAPT (0.41) | BRD4ALDH1A1BRAFRAF1EGFR | |
| SCHEMBL5458888 | 0.84 | KDM4E (0.46) | BRD4KDM4EGLAALDH1A1LMNA | |
| SCHEMBL7215157 | 0.83 | EGFR (0.48) | EGFRAURKA | |
| SCHEMBL4025116 | 0.82 | EHMT2 (0.52) | EGFR | |
| SCHEMBL5218230 | 0.80 | EHMT2 (0.49) | EGFR | |
| SCHEMBL4371022 | 0.78 | ABCB1 (0.43) | FGFR2AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070066633-A1 | Quinazoline compounds | ASTRAZENECA AB | 2007-03-22 | — | — | US | disclosed |
| US-7160889-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2007-01-09 | — | — | US | disclosed |
| EP-1274692-B1 | QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-08-02 | — | — | EP | disclosed |
| US-20030191308-A1 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2003-10-09 | — | — | US | disclosed |
| EP-1274692-A1 | QUINAZOLINE COMPOUNDS | AstraZeneca AB (SE) | 2003-01-15 | — | — | EP | disclosed |
| WO-2001077085-A1 | QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191308-A1 | Quinazoline compounds | CNR1, CBR1, CCR7 | BRD4 352/4885KDM4E 2520/4885GLA 3594/4885 |
| US-20070066633-A1 | Quinazoline compounds | CCR7, CNR1, CBR3 | BRD4 495/4885KDM4E 2943/4885GLA 4231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.